Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 9 | 2026 | 738 | 1.290 |
Why?
|
| Obesity | 10 | 2021 | 1281 | 0.830 |
Why?
|
| Leptin | 4 | 2024 | 89 | 0.780 |
Why?
|
| Hyperglycemia | 1 | 2020 | 109 | 0.580 |
Why?
|
| Bone and Bones | 2 | 2024 | 152 | 0.580 |
Why?
|
| Glucocorticoids | 2 | 2020 | 190 | 0.580 |
Why?
|
| Primary Prevention | 1 | 2017 | 140 | 0.480 |
Why?
|
| Juglans | 3 | 2021 | 14 | 0.440 |
Why?
|
| Health Status | 1 | 2017 | 448 | 0.430 |
Why?
|
| Follistatin | 3 | 2021 | 44 | 0.430 |
Why?
|
| Anti-Obesity Agents | 3 | 2019 | 16 | 0.420 |
Why?
|
| Nephrosis | 1 | 2013 | 4 | 0.410 |
Why?
|
| Diabetes Complications | 1 | 2014 | 106 | 0.400 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 8 | 0.400 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 708 | 0.390 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 35 | 0.390 |
Why?
|
| Risk Assessment | 1 | 2020 | 2116 | 0.380 |
Why?
|
| Hospitalization | 1 | 2020 | 1404 | 0.370 |
Why?
|
| Hypoglycemic Agents | 3 | 2026 | 226 | 0.360 |
Why?
|
| Energy Metabolism | 4 | 2024 | 400 | 0.330 |
Why?
|
| Neurosecretory Systems | 2 | 2024 | 24 | 0.320 |
Why?
|
| Blood Glucose | 4 | 2026 | 502 | 0.320 |
Why?
|
| Weight Loss | 3 | 2019 | 276 | 0.280 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 2 | 2018 | 5 | 0.280 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2018 | 8 | 0.270 |
Why?
|
| Benzazepines | 2 | 2019 | 21 | 0.270 |
Why?
|
| Activins | 2 | 2018 | 55 | 0.260 |
Why?
|
| Fibronectins | 2 | 2017 | 44 | 0.260 |
Why?
|
| Insulin Resistance | 3 | 2021 | 415 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 60 | 0.240 |
Why?
|
| Diabetic Angiopathies | 1 | 2026 | 29 | 0.240 |
Why?
|
| Humans | 27 | 2026 | 65841 | 0.230 |
Why?
|
| Diabetic Retinopathy | 1 | 2026 | 60 | 0.220 |
Why?
|
| Middle Aged | 16 | 2026 | 18500 | 0.220 |
Why?
|
| Double-Blind Method | 7 | 2021 | 747 | 0.220 |
Why?
|
| Liraglutide | 2 | 2026 | 8 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 878 | 0.210 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 326 | 0.200 |
Why?
|
| Incidence | 3 | 2026 | 1433 | 0.200 |
Why?
|
| Autoantibodies | 2 | 2016 | 186 | 0.200 |
Why?
|
| Kidney Diseases | 1 | 2024 | 178 | 0.190 |
Why?
|
| Food Preferences | 2 | 2021 | 52 | 0.190 |
Why?
|
| Female | 19 | 2026 | 34423 | 0.190 |
Why?
|
| Stroke Volume | 1 | 2024 | 346 | 0.190 |
Why?
|
| Risk Factors | 4 | 2026 | 5475 | 0.180 |
Why?
|
| Male | 18 | 2026 | 31409 | 0.180 |
Why?
|
| Homeostasis | 1 | 2024 | 383 | 0.180 |
Why?
|
| Fasting | 2 | 2019 | 52 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2500 | 0.170 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2021 | 6 | 0.170 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2021 | 14 | 0.170 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 922 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 87 | 0.160 |
Why?
|
| Body Weight | 2 | 2019 | 377 | 0.160 |
Why?
|
| Gastrointestinal Hormones | 1 | 2019 | 10 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 504 | 0.150 |
Why?
|
| Metabolic Syndrome | 2 | 2017 | 147 | 0.140 |
Why?
|
| Aged | 8 | 2026 | 15147 | 0.140 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 65 | 0.140 |
Why?
|
| Eating | 1 | 2019 | 140 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 129 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 83 | 0.140 |
Why?
|
| Follistatin-Related Proteins | 1 | 2018 | 22 | 0.140 |
Why?
|
| Appetite Regulation | 1 | 2017 | 8 | 0.130 |
Why?
|
| Nuts | 1 | 2017 | 6 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2026 | 6957 | 0.130 |
Why?
|
| Reproduction | 1 | 2018 | 100 | 0.130 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2017 | 9 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 527 | 0.130 |
Why?
|
| Prognosis | 3 | 2021 | 1793 | 0.130 |
Why?
|
| Functional Food | 1 | 2017 | 39 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2016 | 185 | 0.130 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2016 | 13 | 0.120 |
Why?
|
| Heart Failure | 1 | 2024 | 968 | 0.120 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 52 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 157 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2017 | 169 | 0.120 |
Why?
|
| White Matter | 1 | 2017 | 138 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2017 | 189 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 276 | 0.110 |
Why?
|
| Diet | 1 | 2019 | 540 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1148 | 0.110 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 163 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 1122 | 0.100 |
Why?
|
| WT1 Proteins | 1 | 2013 | 4 | 0.100 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 16 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2016 | 263 | 0.100 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 44 | 0.100 |
Why?
|
| Prevalence | 1 | 2017 | 1454 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 360 | 0.100 |
Why?
|
| Cues | 3 | 2019 | 81 | 0.090 |
Why?
|
| Animals | 4 | 2024 | 21492 | 0.090 |
Why?
|
| Felty Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
|
| Neurons | 1 | 2017 | 935 | 0.090 |
Why?
|
| Brain | 2 | 2017 | 1672 | 0.080 |
Why?
|
| Young Adult | 3 | 2018 | 4883 | 0.080 |
Why?
|
| Postprandial Period | 2 | 2019 | 20 | 0.080 |
Why?
|
| Histones | 1 | 2011 | 497 | 0.070 |
Why?
|
| Energy Intake | 2 | 2019 | 173 | 0.060 |
Why?
|
| United States | 1 | 2020 | 8189 | 0.060 |
Why?
|
| Glucagon-Like Peptides | 1 | 2026 | 8 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2026 | 30 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2026 | 50 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 32 | 0.050 |
Why?
|
| Cognition | 2 | 2019 | 515 | 0.050 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2018 | 226 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2026 | 503 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2026 | 746 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 993 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 901 | 0.050 |
Why?
|
| Adult | 5 | 2019 | 17578 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2739 | 0.040 |
Why?
|
| Glicentin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxyntomodulin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Peptide YY | 1 | 2019 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 5682 | 0.040 |
Why?
|
| Reward | 1 | 2019 | 89 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2019 | 85 | 0.040 |
Why?
|
| Breakfast | 1 | 2017 | 1 | 0.030 |
Why?
|
| Satiety Response | 1 | 2017 | 5 | 0.030 |
Why?
|
| Creatine | 1 | 2017 | 23 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 97 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2322 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 81 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 131 | 0.030 |
Why?
|
| Azathioprine | 1 | 2016 | 27 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 17 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 259 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 375 | 0.030 |
Why?
|
| Lipids | 1 | 2019 | 331 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 30 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1117 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 149 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 322 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 89 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 212 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 108 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 344 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 214 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 462 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 382 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 995 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 364 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 236 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1294 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1503 | 0.020 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 25 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 784 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1569 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2651 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 558 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 140 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3340 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 970 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 396 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 347 | 0.020 |
Why?
|
| Adolescent | 1 | 2011 | 6368 | 0.010 |
Why?
|